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Renal secretion of diphosphonates in rats. Diphosphonates,
characterized by a P—C—P bond, are relatively new experi-
mental drugs used for the treatment of myositis ossificans, dental
calculus, nephrolithiasis and Paget's disease. These compounds
are not metabolized and the fraction which is not taken up by
the skeleton is excreted unchanged in the urine. In the present
study, the renal clearances of two '4C-labelled diphosphonates,
disodium ethane-1-hydroxy-l,l-diphosphonate (CEUDP) and di-
sodium dichloromethylene diphosphonate (CC12MDp) have been
measured in conscious rats. The clearances have been found to
be higher than the glomerular filtration rate (GFR), Cdlpho,phontef
GFR being about 1.5. This observation indicates net tubular
secretion of both drugs. High plasma concentration of EHDP
or CI2MDP significantly depressed CEHDP, whereas CEHDP was
not influenced by varying urine pH, by infusing NH4CI or
NaHCO3, or by simultaneous administration of high doses of
para-aminohippurate (PAH), probenecid, N-methylnlcotm-
amide or Ca-EDTA. High plasma concentration of inorganic
phosphate depressed CEBDP and also depressed the in vitro
ultratiltrability of EHDP. In conclusion, these results provide
evidence of an active renal transport of diphosphonates which
appears distinct from the mechanisms handling organic acids,
organic bases and EDTA in the rat kidney.
Secretion renale des diphosphonates chez le rat. Les diphos-
phonates, caractérisés une liaison P—C—P, sont des mCdica-
ments relativement nouvaux utilisés dans Ic traitement de
Ia myosite ossifiante, des calculs dentaires, de Ia lithiase urinaire
et de Ia maladie de Paget. Ces substances ne sont pas méta-
bolisées et Ia fraction qui n'est pas captée par Ic squelette est
excrétée sans modifications dans l'urine. Dans cc travail les
clearances rénales de deux diphosphonates marques par le 14C,
disodium Cthane-1-hydroxy-l,1-diphosphonate (CEHDP) et di-
sodium dichlorométhylène diphosphonate (CCI2MDP) ont été
mesurées chez des rats conscients, Ces clearances sont super-
ieures au debit de filtration glomérulaire (GFR), le rapport
Cdpbo,pho,,ate/GFR est d'environ 1,5. Cette observation indique
une secretion tubulaire nette des deux drogues. Des concentra-
tions plasmatiques élevCes de EHDP ou de CI2MDP dépriment
significativement CEHDP alors que CEHDP n'est pas influence par
les variations du pH de l'urine, par Ia perfusion de NH4CI ou de
NAHCO3, ou par l'administration simultanée de doses Clevées de
PAH, de probCnécide, de N-methyl-nicotamide ou de Ca-EDTA.
Des concentrations plasmatiques élevées de phosphate inor-
ganique abaissent CEftDP et diminuent aussi l'ultrafiltrabilité in
vitro de EHDP. En conclusion, ces résultats apportent Ia preuve
d'un transport renal actif des diphosphonates qui paralt distinct
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des méchanismes qui assurent Ic transport des acides organiques,
des bases organiques et de I'EDTA dans Ic rein de rat.
Diphosphonates are compounds characterized by a
P—C—P bond. They have recently been introduced in
the treatment of diseases of calcium metabolism. The
rationale lies in their marked inhibitory effect on hy-
droxyapatite crystal growth [1, 2] and dissolution [3,
4] in vitro, and their inhibition of calcium phosphate
deposition [5] and resorption [3,4] in vivo. One diphos-
phonate, disodium ethane-1 -hydroxy-l ,1 -diphospho-
nate (EHDP), has been used successfully in slowing
down or preventing the progress of calcification in
myositis ossificans [6, 7] and calcinosis universalis [8].
It also reduces dental calculus formation [9, 10].
EHDP has been found also to decrease bone turnover
and improve symptoms in patients suffering from
Paget's disease [11, 12].
The bioavailablity and disposition of EHDP have
been studied in four species by Michael, King and
Wakim [13]. They found that EHDP was not appreci-
ably metabolized in the rat. Approximatively one-half
of an absorbed dose went into bone and the remaining
fraction was excreted unchanged in the urine. Only
minute amounts were taken up by soft tissues. Thus,
kidney and bone seemed to play a major role in the in
vivo fate of EHDP.
The present work was designed to study in conscious
rats the renal handling of two 14C-labelled diphospho-
nates, EHDP and dichloromethylene diphosphonate
(C12MDP) by clearance technique. Since both diphos-
phonates were found to be secreted by the kidney, an
attempt was made to characterize the mechanisms
involved. The effect of change of urinary pH and of
several agents known to be secreted by the renal tubule
on the clearance of EHDP was investigated. The results
of these experiments suggest that the secretory me-
chanism of diphosphonates differs from those already
described for organic acids, bases and EDTA.
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Methods
Experimental design. All experiments were per-
formed on male Wistar rats from our own breeding
colony. Prior to the experimental day, the animals were
fed a commercial diet (Altromin 1314) and had free
access to water.
To obtain steady rates of urine flow, the dead space
of the urinary tract was diminished by surgical re-
moval of the dome of the urinary bladder while the
rats were lightly anesthetized with ether, 18 to 24 hr
prior to the experiment. On the experimental day, the
rats were weighed and put into restrictive cages spe-
cially designed for studying renal function in conscious
rats according to a method previously described [14].
Urine was collected anaerobically in tared test tubes
containing 1 ml of Xylol and blood samples were
taken from a hind limb vein.
For infusions, a lateral vein was catheterized. Initi-
ally, a dose (priming) of inulin (80 mg/kg of body wt)
dissolved in 0.15M NaC1 was injected i.v. in a volume
of 2.5 mi/kg of body wt. Solutions containing various
concentrations of 14C-labelled diphosphonates dis-
solved in 0.1 SM NaC1 were then infused by means of a
micropump (Ismatec) with a delivery rate of 3.9 to
4.0 ml/hr. In some experiments the infusion solution
also contained either 120 mivi NH4CI, NaHCO3 or
150 m inorganic phosphate (P1), respectively. In
other experiments, p-aminohippuric acid (PAH), pro-
benecid, N-methylnicotinamide (NMN) or ethylenedi-
aminetetraacetic acid (EDTA) was added to both the
infusion and the priming solution. The diphosphonates
and P1 were not added to the priming solution in order
to avoid the possibility of a local precipitation at the
site of the i.v. injection through the formation of poly-
nuclear complexes of EHDP (see following). The pH
of all solutions was adjusted to 7.4 and the osmolality
was adjusted to 300 to 310 mOsm/liter where necessary
by additon of NaCI. For the P1 solution, pH 7.4 was
obtained by combining Na2HPO4 and NaH2PO4 in
adequate proportions. Inulin was infused at 40 mg/rat
hr in all experiments, while the radioactivity of the di-
phosphonate infused varied from 272 to 1064 nCi/rat
hr.
After 120 mm of equilibration, urine was collected
for two periods (I, II) of 30 to 45 mm each. Blood
samples were taken before the first urine period (1),
between the first and the second (2) and at the end of
the second urine collection period (3). Urine volume
(V), the clearance of inulin (C1) as a measure of
glomerular filtration rate (GFR) and the clearance of
the respective diphosphonate (CEND?, CCI2MDP) were
calculated for each urine period using a standard
formula. The blood concentrations were the arith-
metical mean of samples 1 and 2 for urine I and of 2
and 3 for urine II.
Analytical methods. Urinary volume (V) was deter-
mined by weighing.
Inulin was determined in plasma and urine by the
anthrone method [15]. In preliminary experiments, in-
ulin was also determined by the diphenylamine method
[16] in order to rule out any interference of the diphos-
phonate with the anthrone reagent. The ratio C1
anthrone/C1 diphenylamine did not differ signifi-
cantly from 1.0. A possible interference of EHDP in the
anthrone method for assaying inulin in urine was also
tested in vitro by adding cold EHDP to urine samples
of known inulin concentration. No interference was
found.
14C-labelled diphosphonate activity in urine, plasma
ultrafiltrates or plasma was analyzed by adding urine
or plasma ultrafiltrate (20 .d), or plasma (25 to 50 .d),
to vials containing liquid scintillation solution (10 ml).
The composition of the scintillation fluid was toluene,
600 ml; ethylene-glycolomonoethylether, 400 ml;
naphthalene, 80 g; and Butyl-PBD (Ciba-Geigy),
7.0 g. Duplicate samples were counted in a scintilla-
tion spectrometer (Packard Tricarb, Model 3950). No
quenching was observed when plasma or urine was
added in the volumes stated above. Since Michael
et al [13] had found that 14C-EHDP was not appreci-
ably metabolized in the rat, the radioactivity measured
was considered to be entirely unmetabolized EHDP.
The ultrafiltrable fraction of diphosphonates added
in vivo and in vitro to plasma was measured as follows:
a) In vivo addition: Rats were anesthetized with ether
after a 150-mm infusion period and aortic blood was
obtained while the infusion continued. An Amicon
cell (Model 12, Amicon Corp., Lexington, MA)
fitted with either an XM-50 or an XM-lOOA Diaflo
filter (Amicon Corp., Lexington, MA) was operated
at a gas pressure of 4 atm (1 °/ CO2 and 99% air) to
ultrafilter the plasma. Subsequently, plasma before
ultrafiltration and aliquots of ultrafiltrate were an-
alyzed for '4C-EHDP, and the concentrations of
phosphate and protein were also determined. The
concentration in the ultrafiltrate was expressed as
percent of the plasma concentration. b) In vitro addi-
tion: Ultrafiltrability was likewise determined after
addition of 14C-EHDP or 14C-C12MDP to plasma in
vitro.
Equilibrium dialysis was used to determine the di-
alyzable fraction of '4C-EHDP. A volume of 2.5 ml
was placed into each of two plastic dialysis cells,
separated by a Technicon Cuprophan 105—1058 mem-
brane. The cells were rotated at 130 rpm in a 37°C
incubator whose atmosphere was saturated with 5%
CO2. Plasma was dialyzed against HEPES (N-2-
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hydroxyethylpiperazine-N'-2-ethane sulfonic acid)-
Krebs-Ringer buffer (HEPES, 50 mss; pH 7.4), and
equilibration was reached after 75 mm. Correction
was made for water movements by estimating plasma
protein concentration according to the method of
Lowry et at [17].
Inorganic phosphorus was determined in urine,
plasma ultrafiltrates and plasma as described by Bisaz,
Russell and Fleisch [18]. Calcium concentrations were
estimated by atomic absorption spectroscopy (Perkin
Elmer, Model 290 B). Osmolality of infusion solutions
was measured with an osmometer (Advanced, Model
3W, Advanced Inc., Needham Heights, MA).
Materials. The radioactive diphosphonates used
were as follows: Na2H2EHDP-'4C, sp. activ. 6.1 mCi!
g and Na2H2CI2MDP-'4C sp. activ. 1.6 mCi/g. The
chemical purity of both diphosphonates was greater
than 99%, as assessed by reverse isotope dilution, thin-
layer chromatography, nuclear magnetic resonance
and X-ray diffraction [13]. All chemicals were of
analytical grade.
Statistical analysis. The experimental results are
expressed as mean SEM. Significance of the difference
between groups was determined by Student's t test.
Results
The clearances of the two diphosphonates (CEHDP,
CCIZMDP) infused at a level of 2.14 zmoles/rat hr and
also of inulin (C1) are depicted in Fig. 1. As shown in
Fig. IA, the values Of Cgp, i.e., 12.25 0.53 in period
I and 11.62 0.44 ml/kg. mm (N= 14) in period II, ex-
ceeded C1 which was 9.38 0.50 and 8.70 0.36 ml!
kg. mm, respectively. The fractional excretion of
EHDP represented by the ratio CEIIDP/CIfl was 1.32
0.05 and 1.34± 0.04 for periods I and II, respectively.
Similar results were obtained with CI2MDP. Indeed,
Fig. lB shows that CC12MDP was 12.84±1.32 in period!
and 12.79 1.74 mI/kg mm (N 6) in period II, where-
as C1 was 8.80±0.84 and 7.83 ml/kg.min for
the same periods. The fractional excretion of CI2MDP
(CC12MDP/Crfl) was 1.46±0.06 and 1.53±0.13 for
periods land II, respectively. These results demonstrate
a net tubular secretion of both EHDP and CI2MDP.
They were obtained under steady-state conditions as
indicated by the nonsignificant differences between
period I and period II for the respective clearances.
About 50% of the infused diphosphonates was ex-
creted in the urine.
It is known that the clearance of a substance
secreted by a system exhibiting maximal transport
rate decreases when its plasma concentration increases.
Clearance data obtained when plasma concentrations
of EHDP were altered by infusing doses from 272
(group A) to 3400 nmoles/rat hr (group E) are sum-
marized in Table 1. Increasing the plasma concentra-
tion of EHDP ([EHDP]1) from 0.72 to 3.79 .tM
(groups A, B and C) did not significantly change CERn?
or the ratio CEHDP/CIfl. However, at higher [EHDP]P1
(groups D and E), CERn? and CEHDP/CIfl decreased
significantly when compared to the values observed at
low [EHDP]1 (group A).
Fig 2 illustrates the inverse relationship between
[EHDP]f1 and CEIIDP/CIfl (r= —0.53, P<0.Ol, N=47),
when the individual values of all experiments are re-
presented. As previously indicated in Table 1, the fall
of CERD? when [EHDP]1 increases was not due to
alterations of C1 as the relationship between [EHDP]PI
and CEHDP/CIfl shows the same pattern (Fig. 2). Fig. 2
also demonstrates that all rats but one had a CEHDP/
C1, ratio above that of unity. When EHDP was in-
creased 6.5 times over that of group E, [EHDP]P1 rose
continuously during the experiment from 500 to
1000 M. On the assumption that this increase was a
linear function of time, CEHDP and CEHDP/CIfl were cal-
culated and very low values were obtained. Indeed,
CEDHP was 1.30 0.32 mI/kg mm (period I) and 1.04
0.32 ml/kg. mm (period!!, N= 5). CEHDP/CIfl was 0.16
0.04 mI/kg. mm (period I) and 0.12 0.04 mI/kg. mm
(period II) since C1 remained unchanged at 8.33
0.17 ml/kg.min (period I) and 8.26 ml/kg.min
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Fig. 1. CdjPhO,POflOtO and C1: Fig. L4, EHDP; and Fig. lB.
C12MDP. Following an equilibration period of 120 mm, two
clearance periods (I, II) of 30 mm each were performed as in-
dicated in Methods. The two periods are represented separately.
The infused amount of diphosphonates was 2.14 moles/rat hr
in both groups.
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Table 1. Clearance of EHDP in conscious rats
Group N Dose of
EHDP
[EHDP]1
M
CEHDP
mi/kg. miii
C1
mi/kg. miii
CEHDP/CIfl
nmoles/rat hr
A 9 272 0.72±0.03 14.22±0.85 8.21±0.30 1.74±0.10
B 6 544 1.68±0.05 13.03±0.69 8.74±0.41 1.51
C 9 1072 3,79±0.08 13.52±0.62 8.39±0.21 1.61±0.06
D 14 2144 7.30±0.18 l1.94±0.34b 9.05±0.34 1.34±0.04d
E 8 3400 13.05±0.29 10.33±0.41° 7.44±0.27 1.39±0.03°
All values are mean SEM. CEHDP =clearance of disodium ethane-1-hydroxy-1 ,I -diphosphonate; C1 = clearance of inulin;
[EHDPJ1 = concentration of EHDP in plasma. N= number of rats. For each rat, the average of the three [EHDPJp1 values
and the average of the two clearance periods were used for the calculation of the mean of each group.
b F <0.05 as compared to group A.
° P<0.01 as compared to group A.
dp<o.001 as compared to group A.
(period II). These results could be explained by the
formation of polynuclear complexes with calcium in
this concentration range of EHDP as suggested by the
work of Grabenstetter and Cilley [19]. Presumably,
these large molecular weight complexes would not be
filtered by the kidney glomeruli. For this reason, the
ultrafiltrable fraction of EHDP was not determined in
this condition and the results were not plotted in Fig. 2.
Following the infusion of EHDP, the ultrafiltrable
fraction of groups A, C and E, as described in Table I,
was measured using a Diaflo XM 50 filter. Group A
2.5 7.5 12.5
was 77± 1% (N=4); group C, 63±2% (N=5); and
group E, 67 5% (N= 3). When the diphosphonates
were added to plasma in vitro in order to obtain a
concentration of 5 M, the ultrafiltrable fraction of
EHDP was 64±4% (N=4), and that of CI2MDP
was 83±9% (N=3) with the XM 50 filter (mol wt
cutoff of about 50,000). It was 75 4% (N= 3) for
EHDP and 95 5% (N= 3) for CI2MDP with an
XM 100 A filter (mol wt cutoff of about 100,000).
In two determinations, the dialyzable fraction of
EHDP was 81.5 and 77.2% ([EHDP]1= 1 M) and
74.9 and 78.6% ([EHDPJPI = 100 ILM). These results
correspond approximately to the values of the ultra-
fitrable fraction of EHDP indicated above.
The excretion rate of certain organic acids depends
upon urinary pH, the excretion being higher in alka-
line than in acid urine [20]. Data from clearances
measured in animals perfused with 480 moles/rat hr
of either NaHCO3 or NH4C1 concomitantly with
EHDP at a dose of 1.07 moles/rat hr are given in
Table 2. CEDHP/CIfl was not significantly different in
alkalinized compared to acidified rats. In this latter
group, CEHDP and C1 were slightly lower than in the
group infused with NaHCO3.
The influence of substances secreted by the system
transporting organic acids such as PAH and probene-
cid and by the system secreting organic bases (e.g.,
NMN) on the clearance of EHDP is summarized in
Table 3. PAH up to a dose ratio of 820 (EHDP= I)
probenecid and NMN up to a dose ratio of 100
(EHDP =1) did not affect the CEHDP/CIfl ratio. EDTA
is a substance reported to be secreted without being in-
fluenced by changes in urinary pH and also inde-
pendently of substances of the organic acid and base
group [21]. EDTA, when given as a calcium complex
at a dose ratio of 31 (EHDP = 1), did not influence
CEHDP. Total plasma calcium concentration was the
2.0
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Fig. 2. CEnDp/CJfl related to plasma concentration of the drug.
Each point represents the mean of two clearance periods in one
rat.
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Observation NaHCO3 (N= 9) NH4CI (N= 9)
Urine pH 7.91 0.05 6.10± 0.06b
CEHDP 11.03±0.73 9.35±0.77C, 8.48±0.47 7.04±0.33°
CEHDP/CIn 1.30±0.06 1.36±0.13
a All values are mean SEM. CaHDP = clearance of disodium
ethane-1-hydroxy-1,1-diphosphonate; C1,,= clearance of inulin.
N= number of rats. For each rat the average of the two clear-
ance periods was used for the calculation of the mean of the
group.bP<0.001 as compared to the alkalinized group.
P< 0.05 as compared to the alkalinized group.
same in both groups (EDTA, 10.16 mg/100 ml,
N=4; control, 10.18 mg/100 ml, N—°4).
As shown in Fig. 1B, C12MDP, the other diphos-
phonate, is also secreted. At a dose ratio of 31
(EHDP= 1), equal to that used with EDTA, CI2MDP
did significantly decrease CEHDP without altering C,
(Fig. 3).
Inorganic phosphate (P1) is another substance for
which evidence of tubular secretion in the rat nephron
has been presented very recently [22]. Results concern-
ing the influence of i.v. loading of P1 on renal handling
of EHDP are summarized on Table 4. The data of the
control group show that stable plasma concentrations
and clearance values of EHDP and P1 were reached in
two clearance periods (I, II) measured after two hours'
equilibration. In the P1-loaded group, [EHDP]P1 was
significantly higher in all three blood samples (1, 2 and
3) and steady-state concentrations were not achieved.
Assuming that the fall of [EHDP]P1 was a linear func-
tion of time, which seems likely from the data pre-
sented, clearance calculations show that CEHDP was
significantly lower in P1-loaded animals as compared
to the controls. As C1, was the same in both groups,
the fractional excretion of EHDP was significantly
diminished in the Pt-loaded group (P <0.001) and this
effect was most striking in period I where it fell signi-
ficantly below unity (P <0.02). Note that the renal
handling of P1 remained constant during periods I and
II in both groups.
In another similar experiment, the ultrafiltrability
(XM 50 Diaflo ultrafilter) of EHDP and P1 was
measured at the end of a clearance period in the ab-
sence and presence of P1 loading. In the absence of P1
loading, CEHDP/CIfl was 1.96±0.20 ml/kg. mm and the
ultrafiltrable fraction of EHDP was 63±2% (N= 5).
Table 3. Effect of various substances secreted in rat kidney on CEHDP/CI,, ratio in ratsa
Substance and total dose
per 1 experiment, moles
EHDP total
dose per 1 cx-
periment, Lmo1es
Dose ratio
(EHDP= 1)
Treated CEHDP/CIfl Control CEHDp/CIfl
PAH 925b 9.7 95 1.28±0.05 (N=5) 1.29±0.03 (N=4)
1000° 1.2 820 1.83 (N=4) 1.84±0.06 (N=4)
Probenecid 124d 10.0 12 1.35±0.17 (N=3) 1.23±0.07 (N=4)
124d 1.2 100 2.40±0.15 (N=4) 2.08±0.08 (N=4)
NMN 129e 1.2 105 1.62±0.06 (N=6) 1.55±0.15 (N=5
Ca-EDTA 88.5 2.5 36 1.44±0.07 (N=5) 1.38±0.13 (N=5)
a Substances were administered in 0.15 M NaCI solution as follows: PAH: b "priming" 25 moles/rat+ infusion 900 molesf
rat; ° "priming" 75 moles/rat + infusion 925 imoles/rat. Probenecid: d "priming" 100 moles/rat + infusion 24 moles/rat.NMN: °
"priming" 7 moles/rat + infusion 122 .tmoles/rat. Ca-EDTA: "priming" 15 moles/rat + infusion 73.5 moles/rat.
All values are mean SEM. N= number of rats. For each rat the average of clearance periods was used for the calculation
of the mean of the group.
Table 2. Effect of systemic acidification and alkalinization on the
renal handling of EHDP in rats°
-F
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Control CI2MDP
Fig. 3. Influence of CI2MDP-loading on CEHDP, Total dose of
EHDP per experiment was 2.45 moles in both control and ex-
perimental (+ CI2MDP) groups. The latter received in addition
a total dose of CI2MDP of 76 moles ("priming" 4 moles/rat +
infusion 72 moles/rat). Dose ratio was 31:1 (EHDP= 1).
Number of rats: control, 6; C12MDP, 5. Clearances were cal-
culated as explained in legend to table 2. **p<o.®1.
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Table 4. Influence of an infusion of inorganic phosphate (P1) on the renal handling of EHDP in ratsa
Group
Clearance period
Plasma sample
Control (N
I
'l '2'
= 9)
II
3'
P1-loaded (N=9)
I H
3'
Plasma-EHDP, ILM 3.68±0.15 3.67±0.16 3.90±0.10 9.96± I.14b 8.05±0.97e 5.42±0.68d
Plasma-P1, mii 2.69±0.10 2.67±0.08 2.55±0.09 5.63±0.09" 5.78±0.13" 6.14±0.24"
Plasma-Ca, m 2.23±0.12 1.59±0.17
C1, ml/kg.min 8.39±0.16 8.37±0.28 8.41±0.20 8.52±0.24
CEED?, ml/kg.min 13.87±0.61 13.16±0.65 5.70±0.83" 8.42± 1.03'
CEHlp/C,, 1.65± 0.07 1.57± 0.05 0.68±0.10" 1.00± 0.13"
C,,,, mu kg.min 1.38±0.09 1.35±0.17 8.39±0.16" 8.63 0.29"
C,,1/C, 0.16± 0.01 0.16±0.02 1.00±0.01" 1.02±0.04"
a All values are mean±sEM. Both control and P,-loaded animals received EHDP i.v. at a dose of 18 nmoles/min. The P,-loaded rats
were given P, at a dose of 10 moles/min. For the P, solution, pH 7.4 was obtained by combining Na2HPO4 and NaH2PO4 in adequate
proportion.b P<0.001 as compared to the respective control value.
P <0.01 as compared to the respective control value.
P <0.05 as compared to the respective control value.
In the P1-loaded group, CEHDP/CIfl was 0.82 0.18 mu
kg. miii but the ultrafiltrable fraction of EHDP was
markedly reduced at 28±8% (N'= 3). No significant
difference was observed between the two groups with
respect to the ultrafiltrability of P1 (unloaded: 95 2%,
N=5; P,-loaded: 91 3%, N=3).
Discussion
The data presented in Figs. 1 and 2 and Table I in-
dicate that the diphosphonates EHDP and C12MDP
are eliminated in the urine not only by glomerular
filtration but also by tubular secretion. Even if an error
of 10% in the clearance procedure were to occur, only
one out of 47 animals studied would display a CEHDP/
C11, ratio below that of unity (Fig. 2). In addition,
studies using ultrafiltration and dialysis techniques
suggest an incomplete ultrafiltrability of both diphos-
phonates. The extrapolation of these results obtained
in vitro to the actual glomerular filtration fraction of
either diphosphonate suggests that the relative im-
portance of the secretory process is, in fact, under-
estimated, when only the ratio Cdjphosphoflate/CIfl is con-
sidered. But as it is uncertain to what extent the ultra-
filtrability determined in vitro may reflect the in vivo
process, no "corrective" calculations were attempted.
The trend of CEHDP and CEHDP/C1,, to decrease at
plasma concentrations above 7.5 M (Table 1, Fig. 2)
suggests that the secretory process for EHDP might be
saturable. However, in spite of a dialyzable fraction of
EHDP which appears similar at either 1 or 100 M,
this slight reduction in CEHDP could be due to a small
change in the glomerular ultrafiltrability which is
difficult to assess in vivo and also may not be detected
by in vitro studies.
The marked fall of CEHDP at [EHDP]I higher than
400 M is very likely due to the formation of poly-
nuclear complexes of EHDP with calcium as described
by Grabenstetter et al [19].
The net renal secretion of diphosphonates suggests
an active renal cellular uptake of these drugs. Support
for this concept comes also from incubation of rat
renal cortical slices with 14C-EHDP in vitro [23].
In an attempt to characterize the mechanism of this
tubular secretion, two types of experiments were initi-
ated:
First, the influence of a variable urinary pH on the
excretion of EHDP was examined. Other investiga-
tions have described four pKa values for EHDP,
namely, 11.16; 7.00 and 2.80 [24]; and 1.7 [25]. In an
infusion solution, at pH 7.4, therefore, EHDP should
be present as an equilibrium mixture of the anionic
species (mainly bivalent and trivalent, the nonionic
fraction being negligible). However, the state of EHDP
in plasma is very difficult to predict, since besides a
possible binding to protein, this diphosphonate has a
high affinity for bivalent cations, such as Ca + + and
Mg + [25]. Even though part of the circulating form
of EHDP would be a mixture of the anionic species,
one would not expect that the phenomenon of passive
tubular secretion by nonionic diffusion with subse-
quent trapping would take place because of the pK
values just listed. On the other hand, modification of
the urinary pH within a range of 6.10 to 7.9 could
alter the proportion of the various species of EHDP
present in the tubular fluid. This might change the
overall tubular permeability of EHDP and thereby in-
12 Troehier et a!
fluence its excretion. However, our findings do not
show an influence of urinary pH on the renal handling
of EHDP. Furthermore, in experiments not reported
here, we have found no additional fall in urinary pH
when the dose of NH4C1 was increased twofold. Under
these latter conditions, there was an increased fall in
C1, but CEJIDP/CIfl was not significantly different
from the data presented in Table 3.
Second, the effect of high doses of substances belong-
ing to the two well-described renal secretory systems
[20] were tested on CEHDP. PAH and probenecid be-
long to the system secreting several organic acids [26],
whereas N-methylnicotinamide (NMN) shares the
system which secretes organic bases [26]. As far as
their free circulating form, at pH 7.4, is considered,
these compounds should be entirely dissociated into
monovalent anions (cations) as their pKa (pKb) values
are as follows: PAH, 3.8; probenecid, 3.4 [27]; NMN,
strong base, [28]. None of these substances altered
CEHDP and neither did Ca-EDTA, which has been
suggested to be secreted at least in the rat by a third
separate system [20, 29] about which there is still
some controversy [30].
Inorganic phosphate (P1) has very recently been re-
ported to be secreted in the rat nephron [22], but its
secretory pathway has not yet been identified. P1 is
dissociated at pH 7.4 mainly into its monovalent and
bivalent forms, and except for the fraction which is
complexed by sodium and divalent cations, P1 in the
plasma is ionized [31]. Of interest is our finding that
an infusion of P1 depressed CEHOF, the mechanism as
yet being unknown. Among several interpretations,
one could speculate that diphosphonates and P1 share
a common transport mechanism at the renal tubular
level. This effect could also be due to a reduced glomer-
ular ultrafiltrability of EHDP. In vitro experiments
would support this latter possibility as the ultrafiltrable
fraction of EHDP was markedly lowered in plasma of
P1-loaded rats.
The question arises whether these results have a rel-
evance with respect to the hyperphosphatemia seen in
humans treated with EHDP. Either P1 and EHDP
share a common transport mechanism for secretion
as discussed above or, alternatively, they may inhibit
the transport of each other. However, in rats, while P1
decreases CEHDP, the opposite could not be demon-
strated in our conditions by either chronic subcutaneous
or acute i.v. administration of variable doses of EHDP
in unloaded and P1-loaded intact animals (unpublished
data). It still remains possible that the inhibition of
one compound is not of the same magnitude in the
two species, so that the plasma concentrations of
EHDP obtained in the rat would not be sufficient to
inhibit P1 transport.
Finally, the other diphosphonate, CI2MDP, which
is also shown in the present work to be secreted, was
found to affect CEHOP. Therefore, one can suspect that
the influence of CI2MDP on CEHDP reflects the exis-
tence of a common renal transport pathway shared by
these two diphosphonates.
In conclusion, these studies demonstrate that di-
phosphonates are secreted by the renal tubule. The
secretory mechanism involved is as yet unknown.
However, it appears to be different from those hand-
ling organic acids, organic bases and EDTA.
Acknowledgments
Part of this investigation was presented at the
Seventh Annual Meeting of the European Society for
Clinical Investigation, Rotterdam, 1973 (abstract
published in Eur J C/in Invest 3:272, 1973) and at the
Fifth Annual Meeting of the Swiss Society of Nephrol-
ogy, Lausanne, 1973 (abstract published in Kidney
mt 5:313, 1974). This work was supported by Public
Health Service grant AM 07266 from the National
Institutes of Health, by Schweizerischer Nationalfonds
für wissenschaftliche Forschung grant 3.326.70 and by
the Procter and Gamble Company. Miss T. Rolli pro-
vided technical assistance.
Reprint requests to Dr. U/rich Troehier, Department of Patho-
physiology, University of Berne, Murtenstrasse 35, CH-3012
Berne, Switzerland.
References
1. FRANCIS MD: The inhibition of calcium hydroxyapatite
crystal growth by polyphosphonates and polyphosphates.
Calcif Tissue Res 3:151—162, 1969
2. FRANCIS MD, RUSSELL RGG, FLEISCH H: Diphosphonates
inhibit formation of calcium phosphate crystals in vitro
and pathological calcification in vivo. Science 165:1264—
1266, 1969
3. FLEISCH H, RUSSELL RGG, FRANCIS MD: Diphosphonates
inhibit hydroxyapatite dissolution in vitro and bone re-
sorption in tissue culture and in vivo. Science 165:1262—
1264, 1969
4. RUSSELL RGG, MUHLBAUER RC, BISAZ S, WILLIAMS DA,
FLEISCH H: The influence of pyrophosphate, condensed
phosphates, phosphonates and other phosphate compounds
on the dissolution of hydroxyapatite in vitro and on bone
resorption induced by parathyroid hormone in tissue culture
and in thyroparathyroidectomised rats. Calcif Tissue Res 6:
183—196, 1970
5. FLEISCH H, RUSSELL RUG, BISAZ S, MUHLBAUER RC,
WILLIAMS DA: The inhibitory effect of phosphonates on the
formation of calcium phosphate crystals in vitro and on
aortic and kidney calcification in vivo. Eur J C/in Invest 1:
12—18, 1970
6. RUSSELL RGG, SMITH R, BISHOP MC, PRICE DA, SQUIRE
CM: Treatment of myositis ossificans progressiva with a
diphosphonate. Lancet 1:10—12, 1972
Tubular secretion of diphosphonates 13
7. GEHO WB, WHITESIDE JA: Experience with disodium eti-
dronate in diseases of ectopic calcification, in Clinical
Aspects of Metabolic Bone Disease. Amsterdam, Inter-
national Congress Series No. 270of Excerpta Medica, 1973,
pp. 506—511
8. CRAM RL, BARMADA R, GEHO WB, RAY RD: Diphos-
phonate treatment of calcinosis universalis. N Eng! J Med
285: 1012—1013, 1971
9. MUHLEMANN HR, BOWLES D, SCHAIT A, BERNIMOULIN JR:
Effect of diphosphonate on human supragingival calculus.
Helv OdontolActa 14:31—33, 1970
10. STURZENBERGER OP, SWANCAR JR, REITER G: Reduction of
dental calculus in humans through the use of a dentifrice
containing a crystal-growth inhibitor. J Periodontol 42:416—
419, 1971
11. SMITH R, RUSSELL RGG, BISHOP MC, WooDs CG, BISHOP
M: Paget's disease of bone: Experience with a diphos-
phonate (disodium etidronate) in treatment. Q J Med 42:
235—256, 1973
12. ALTMAN RD, JOHNSTON CC, KHAIRI MRA, WELLMAN H,
SERAFINI AN, SANKEY RR: Influence of disodium etidronate
on Paget's disease of bone. NEngl J Med 289: 1379—1384,
1973
13. MICHAEL WR, KING WR, WAKIM JM: Metabolism of
disodium ethane I -hydroxy-1 ,1-diphosphonate (disodium
etidronate) in the rat, rabbit, dog and monkey. Toxicol
App!Pharmacol 21:503—515, 1972
14. BONJOUR JP, REGOLI D, ROCH-RAMEL F, PETERS G: Pre-
requisites for the natriuretic effect of val-5-angiotensine II
amide in the rat. AmJPhysiol2l5:1133—1138, 1968
15. RICHTERICH R: Klinische Chemie (3rd ed). Basel, S. Karger
AG, 1971, pp. 279—280
16. HARRISON HE: A modification of the diphenylamine method
for determination of inulin. Proc Soc Exp Biol Med 49:111—
114,1942
17. LowRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ:
Protein measurement with the folin phenol reagent. J Biol
Chem 193:265—275, 1951
18. BISAZ S, RUSSELL ROG, FLEISCH H: Isolation of inorganic
pyrophosphate from bovine and human teeth. Arch Oral
Biol 13:683—696, 1968
19. GRABENSTETTER RJ, CILLEY WA: Polynuclear complex for-
mation in solutions of calcium ion and ethane-1-hydroxy-1,
1 -diphosphonic acid: 1. Complexometric and pH titrations.
JPhys Chem 75:676—682, 1971
20. PITTS RF: Physiology of the Kidney and Body Fluids (2nd
ed). Chicago, Year Book Medical Publishers, 1968, pp. 129—
143
21. PITTS RF: Physiology of the Kidney and Body Fluids (2nd
ed). Chicago, Year Book Medical Publishers, 1968, p. 137
22. BOUDRY JF, TROEHLER U, Tou&m M, FLEISCH H, BONJOUR
JP: Evidence for renal tubular secretion of inorganic
phosphate in the rat. Clin Sci, in press
23. TROEHLER U, R0LLI T, TOUABI M, BONJOUR JP, FLEISCH H:
Net renal secretion of diphosphonate in rats: A new tubular
secretory mechanism (abstract). Kidney liii 5:313, 1974
24. GRABENSTETTER RJ, QUIMBY DT, FLAUrr TJ: The acid
dissociation constants of substituted methanediphosphonic
acids. JPhys Chem 71:4194, 1967
25. Stability Constants of Metal-Ion Complexes, edited by
SILLEN LG, MARTELL AE, London, The Chemical Society,
1971, suppl. 1, pp. 1—273
26. VAN Os GAJ, ARIENS EJ, SIM0NIs AM: Drug transference:
Distribution of drug in the organism: Active transport, in
Molecular Pharmacology, edited by ARINS EJ, New York,
Academic Press mc, 1964, vol. 1, p. 43
27. VAN O GAJ, ARIgNS EJ, SIMONIS AM: Drug transference:
Distribution of drug in the organism: Passive processes, in
Molecular Pharmacology, edited by ARIENS EJ, New York,
Academic Press mc, 1964, vol. 1, p. 14
28. PETERS L: Renal tubular excretion of organic bases. Pharma-
colRev 12:1—35, 1960
29. HELLER J, VOSTAL J: Renal excretion of calcium-disodium-
ethylenediaminetetraacetic acid: A new tubular secretory
mechanism? Experientia 20:99, 1964
30. ARONSON HL, AHItENS FA: The mechanism of renal trans-
port and excretion of ethylene diamine tetraacetate with
interspecies comparisons. Toxico! App! Pharmacol 18: 1—9,
1971
31. MARSHALL RW, NORDIN BEC: The state of organic phos-
phate in plasma and its relation to other ions, in Phosphate
et Métabolisme Phospho-calcique, edited by HIAC0 DJ,
Paris, Sandoz Editions, 1971, pp. 127—1 38.
